Pharming Group N.V..
PHAR.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes innovative protein replacement therapies and precision medicines, focusing on areas with high unme...Show More
Better Health for All
0
No evidence available to assess Pharming Group N.V. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Pharming Group N.V. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
40
Pharming Group N.V. reported a CEO to mean employee compensation ratio of 8.9:1 in 2024, which is a decrease from 12.0:1 in 2023.
1
The company also achieved an employee engagement score of 86% in 2024.
2
No specific, quantifiable data was provided for living wage coverage, collective bargaining share, safety incident rate, pay equity ratio, turnover rate as a percentage, labor violation incidents, insecure contract share, or health insurance coverage.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Pharming Group N.V. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess Pharming Group N.V. on Honest & Fair Business.
Kind to Animals
0
Insufficient evidence to determine a value score for Pharming Group N.V. regarding Kind to Animals. No articles or relevant information found. A neutral score of 0 is assigned.
Materiality Analysis: Company Summary (75-100 words): Pharming Group N.V. is a biopharmaceutical company focused on developing and commercializing protein replacement therapies and precision medicines for rare diseases. Their primary product is RUCONEST, a recombinant C1 esterase inhibitor. They also market Joenja (leniolisib) and are developing OTL-105, a gene therapy. The company collaborates with Novartis and Orchard Therapeutics. Pharming's operations involve research, development, manufacturing, and commercialization of pharmaceutical products, primarily targeting rare genetic conditions. Their activities are concentrated in the US, Europe, and internationally.
Peer Comparison (50-75 words): Compared to other biopharmaceutical companies, Pharming's animal welfare impact is likely average. Most companies in this sector utilize animal testing during drug development and safety assessments. Some peers may be investing more heavily in alternative testing methods or focusing on therapies that require less animal involvement.
Materiality Assessment (1-2 clear sentences): Pharming's business model has a medium level of conflict with the "Kind to Animals" value due to the potential for animal testing in drug development and manufacturing, but this is somewhat mitigated by their focus on rare diseases and advanced therapies.
Detailed Rationale (150-200 words): As a biopharmaceutical company, Pharming is likely to engage in animal testing during the research, development, and safety assessment phases of its products, which directly conflicts with the "Kind to Animals" value. The development of biologics and gene therapies often requires animal models to evaluate efficacy and safety. While Pharming's focus on rare diseases might lead to smaller patient populations and potentially less extensive testing compared to companies developing blockbuster drugs, the fundamental need for animal testing remains. The company's collaborations with Novartis and Orchard Therapeutics could also involve animal testing activities. However, the company may also be investing in or utilizing alternative testing methods to reduce animal usage, which would positively influence their alignment with the value. Transparency regarding their animal testing policies and practices is crucial for a comprehensive assessment.
Value Interaction Notes (if applicable, 25-50 words): Developing treatments for rare diseases (addressing human health needs) may necessitate animal testing, creating a tension between "Kind to Animals" and values related to human well-being.
Scoring Boundary Flags (if applicable, 25-50 words): Scores above 6 would be illogical unless Pharming demonstrates a complete absence of animal testing and a strong commitment to alternative methods. Scores below 2 would be inappropriate if they have standard animal testing practices for pharmaceuticals.
No War, No Weapons
0
The provided articles describe Pharming Group N.V. as a biopharmaceutical company focused on developing therapies for rare diseases.
1
The documents detail its product development, financial information, corporate governance, and ethical code of conduct. However, none of the articles contain specific, concrete data points or explicit statements regarding any of the KPIs related to arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, peacebuilding investments, or any other aspect of the "No War, No Weapons" value. Therefore, no KPIs can be scored based on the evidence provided.
Planet-Friendly Business
0
Pharming Group N.V. has developed an understanding of its baseline greenhouse gas emissions for Scope 1, 2, and 3 based on 2022 data and plans to formalize this process.
1
The company's owned rabbit milk production facility purchases electricity from 100% renewable energy sources.
2
Pharming's Headquarters in Leiden is located in a building that received the Breeam-NL label 'excellent'.
3
The company has a comprehensive Code of Conduct that emphasizes environmental protection and compliance with all applicable environmental laws, regulations, and codes.
4
Pharming is preparing for its first mandatory ESG report in 2025, in accordance with CSRD requirements, and has performed a double materiality assessment.
5
The company acknowledges the importance of minimizing global warming in line with the Paris Agreement and will set realistic targets for 2025 and beyond.
6
Pharming incurred additional impairment expenses related to its DSP facility in Oss, Netherlands, amounting to US$4.7 million in 2023 compared to US$3.9 million in 2022, and is exploring alternative utilization possibilities for this asset.
7
However, no specific quantitative data or verifiable actions were provided that directly align with the quantitative thresholds of the given KPIs for the company as a whole.
Respect for Cultures & Communities
0
No evidence available to assess Pharming Group N.V. on Respect for Cultures & Communities.
Safe & Smart Tech
0
Pharming Group N.V.'s Code of Conduct and Privacy Statement outline user rights, including access, correction, and erasure of data, and emphasize compliance with privacy laws such as GDPR and CCPA.
1
The company also states its commitment to collecting only necessary data and limiting retention.
2
A job posting for a Corporate Compliance & Privacy Officer further highlights the company's focus on adhering to EU and global privacy requirements and listing requirements for Euronext and Nasdaq.
3
However, no specific details or quantitative data are provided regarding the extent of user control, specific data retention periods, or the effectiveness of compliance programs.
Zero Waste & Sustainable Products
-60
Pharming has one lab certified at the highest level (Green) by My Green Lab.
1
The percentage of total facilities with zero waste certification is not specified.
2
The company has no waste disposal violations reported in the past three years.
3
Pharming has vague waste reduction goals, aiming to reduce carbon emissions over time and prevent waste, but lacks specific targets or deadlines.
4
The company has waste requirements for all direct suppliers, expecting them to comply with ethical standards and environmental laws.
5
Basic disposal information is provided to customers, with a commitment to provide factual, objective, and evidence-based scientific information to stakeholders.
6